Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Benitec Biopharma Ltd ADR (BNTC)

Benitec Biopharma Ltd ADR (BNTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 438,851
  • Shares Outstanding, K 33,862
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,920 K
  • EBIT $ -46 M
  • EBITDA $ -46 M
  • 60-Month Beta 0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.59

Options Overview Details

View History
  • Implied Volatility 233.79% (-37.71%)
  • Historical Volatility 93.62%
  • IV Percentile 71%
  • IV Rank 58.02%
  • IV High 342.38% on 11/07/25
  • IV Low 83.70% on 09/03/25
  • Expected Move (DTE 7) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 2.32
  • Today's Open Interest 126
  • Open Int (30-Day) 82
  • Expected Range 11.98 to 11.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.25
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +36.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.54 +3.81%
on 12/02/25
13.95 -14.12%
on 11/19/25
-1.46 (-10.86%)
since 11/12/25
3-Month
11.53 +3.86%
on 11/06/25
16.76 -28.52%
on 10/27/25
-1.87 (-13.50%)
since 09/12/25
52-Week
9.70 +23.51%
on 02/13/25
17.15 -30.15%
on 06/10/25
-0.37 (-3.00%)
since 12/12/24

Most Recent Stories

More News
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use...

BNTC : 11.98 (-7.56%)
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing...

BNTC : 11.98 (-7.56%)
Benitec Biopharma Inc. Announces Proposed Public Offering

HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing...

BNTC : 11.98 (-7.56%)
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has...

BNTC : 11.98 (-7.56%)
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...

BNTC : 11.98 (-7.56%)
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing...

BNTC : 11.98 (-7.56%)
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study...

BNTC : 11.98 (-7.56%)
Benitec Biopharma Provides Operational Updates

BNTC : 11.98 (-7.56%)
Benitec Biopharma Releases Third Quarter 2025 Financial Results

BNTC : 11.98 (-7.56%)
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

BNTC : 11.98 (-7.56%)

Business Summary

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B,...

See More

Key Turning Points

3rd Resistance Point 13.45
2nd Resistance Point 13.25
1st Resistance Point 13.10
Last Price 11.98
1st Support Level 12.76
2nd Support Level 12.56
3rd Support Level 12.41

See More

52-Week High 17.15
Fibonacci 61.8% 14.30
Fibonacci 50% 13.42
Fibonacci 38.2% 12.55
Last Price 11.98
52-Week Low 9.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar